The dawn of a new era for biological drugs in allergology

The emergence of biological drugs has transformed the management of severe allergic conditions, including asthma, atopic dermatitis, and eosinophilic esophagitis. Recently, the approval of omalizumab to treat multiple food allergies, in the United States, was a breakthrough in enhancing tolerance and reducing severe reactions. Dupilumab also shows promise in reducing IgE levels and symptom severity in patients with atopic dermatitis and food allergies, potentially offering a therapeutic avenue. Additionally, studies suggest dupilumab’s role in mitigating the atopic march, especially in adolescents with early-onset and severe atopic dermatitis, raising questions about the optimal window for intervention and duration of treatment. The approval of dupilumab for children aged 6 months to 5 years opens avenues for further research on preventing the atopic march from infancy